Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register allows you to search for protocol and results information on:
  • interventional clinical trials that are conducted in the European Union (EU) and the European Economic Area (EEA);
  • clinical trials conducted outside the EU / EEA that are linked to European paediatric-medicine development.
  • Learn   more about the EU Clinical Trials Register   including the source of the information and the legal basis.


    The EU Clinical Trials Register currently displays   35419   clinical trials with a EudraCT protocol, of which   5814   are clinical trials conducted with subjects less than 18 years old.
    The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2005-006077-27
    Sponsor's Protocol Code Number:BS559
    National Competent Authority:Slovakia - SIDC (Slovak)
    Clinical Trial Type:EEA CTA
    Trial Status:Completed
    Date on which this record was first entered in the EudraCT database:2006-05-16
    Trial results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedSlovakia - SIDC (Slovak)
    A.2EudraCT number2005-006077-27
    A.3Full title of the trial
    A MULTICENTRE, DOUBLE-BLIND, DOUBLE-DUMMY, RANDOMISED, PARALLEL-GROUP STUDY TO DETERMINE THE THERAPEUTIC EQUIVALENCE BETWEEN FLUTICASONE
    PROPIONATE, 100 µg TWICE DAILY DELIVERED VIA A PRESSURISED METERED DOSE INHALER (MERCK GENERICS) WITH A REFERENCE FLUTICASONE PROPIONATE
    FORMULATION, 100 µg TWICE DAILY ADMINISTERED FROM A REFERENCE PRESSURISED METERED DOSE INHALER IN INHALED CORTICOSTEROID NAÏVE PAEDIATRIC PATIENTS WITH MILD TO MODERATE PERSISTENT ASTHMA (APOLLO STUDY)
    A.3.2Name or abbreviated title of the trial where available
    APOLLO
    A.4.1Sponsor's protocol code numberBS559
    A.7Trial is part of a Paediatric Investigation Plan Information not present in EudraCT
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorMerck Generics
    B.1.3.4CountryUnited Kingdom
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing support
    B.4.2Country
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisation
    B.5.2Functional name of contact point
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Information not present in EudraCT
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameFluticasone propionate
    D.3.4Pharmaceutical form Pressurised inhalation, suspension
    D.3.4.1Specific paediatric formulation Information not present in EudraCT
    D.3.7Routes of administration for this IMPInhalation use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNFluticasone propionate
    D.3.10 Strength
    D.3.10.1Concentration unit µg microgram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number50
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) Information not present in EudraCT
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy Information not present in EudraCT
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product Information not present in EudraCT
    D.3.11.8Extractive medicinal product Information not present in EudraCT
    D.3.11.9Recombinant medicinal product Information not present in EudraCT
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product Yes
    D.3.11.13.1Other medicinal product typeSynthetic glucocorticosteroid
    D.IMP: 2
    D.1.2 and D.1.3IMP RoleComparator
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Information not present in EudraCT
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameFlixotide®
    D.3.4Pharmaceutical form Pressurised inhalation, suspension
    D.3.4.1Specific paediatric formulation Information not present in EudraCT
    D.3.7Routes of administration for this IMPInhalation use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNFluticasone propionate
    D.3.9.1CAS number 80474-14-2
    D.3.9.3Other descriptive nameFlixotide®
    D.3.10 Strength
    D.3.10.1Concentration unit µg microgram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number50
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) Information not present in EudraCT
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy Information not present in EudraCT
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product Information not present in EudraCT
    D.3.11.8Extractive medicinal product Information not present in EudraCT
    D.3.11.9Recombinant medicinal product Information not present in EudraCT
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product Yes
    D.3.11.13.1Other medicinal product typeSynthetic glucocorticosteroid
    D.8 Information on Placebo
    D.8 Placebo: 1
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboPressurised inhalation, suspension
    D.8.4Route of administration of the placeboInhalation use
    D.8 Placebo: 2
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboPressurised inhalation, suspension
    D.8.4Route of administration of the placeboInhalation use
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Asthma
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 8.1
    E.1.2Level LLT
    E.1.2Classification code 10003555
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    The primary aim of the study is to demonstrate the therapeutic equivalence of a generic formulation of fluticasone propionate, 100 µg twice daily administered from a pressurised metered dose inhaler (pMDI) (Merck Generics) with a reference fluticasone propionate formulation, 100 µg twice daily administered from a reference pMDI in patients with mild to moderate persistent asthma bronchiale.
    E.2.2Secondary objectives of the trial
    The secondary aim of the study is to evaluate safety and tolerability of the generic formulations in comparison with the reference formulations in terms of vital signs, 24-hour urinary free cortisol levels (expressed as cortisol:creatinine ratio), physical examination and adverse events (including oral candidiasis).
    E.2.3Trial contains a sub-study Information not present in EudraCT
    E.3Principal inclusion criteria
    Patients will be eligible for enrolment into the study if all of the following criteria are met at the screening visit (Visit 1):
    1. Male and female paediatric patients aged 4 to 16 years (inclusive)
    2. Documented clinical history of reversible obstructive airways disease of at least 2 weeks duration at the time of the Visit 1
    3. Inhaled corticosteroid naïve
    4. Ability to correctly use the pMDIs (this can be with or without the aid of a device spacer as appropriate, however the use/non-use of a spacer device must remain constant throughout the patient’s participation in the study)
    5. Written informed consent/assent for participation in the study from the patient/parent/legal guardian (as appropriate)

    The following must be demonstrated after withholding use of short-acting β2- agonists for the preceding 4 hrs. If a patient fails to meet the washout criteria at the screening visit, another appointment should be made to obtain clinical spirometry data:

    6. FEV1 between 60% and 90% of the predicted value for their age, height and
    gender at screening, (refer to section 5.8.3.1.2 of the protocol)

    Note: Patients must not enter the run-in period without meeting this criterion

    7. Reversibility: demonstrated by a ≥ 12% increase in FEV1 ≥ 10 min and up to 15 minutes after inhalation of up to 400 µg salbutamol (Ventolin Evohaler®) via a spacer (refer to section 5.8.3.1.2 of the protocol)

    Note: Patients with a study-qualifying FEV1 may enter the run-in period without having demonstrated reversibility. Reversibility can be determined at screening, during the run-in period or at the randomisation visit. At the investigator’s discretion, if a patient fails to meet the ≥ 12% threshold, the reversibility tests may be repeated as many times as necessary during this period. Once reversibility has been demonstrated the reversibility test should not be repeated.
    E.4Principal exclusion criteria
    Patients will be excluded from participation if any of the following apply at screening (Visit 1):

    1. Current or prior use of inhaled corticosteroids (for routine control of their asthma)
    2. Evidence of an unknown disease requiring further clinical evaluation (e.g. previous
    laboratory abnormality or a physical examination or vital sign finding)
    3. Concomitant severe diseases or diseases which the investigator believes are contraindications for the use of inhaled steroids or which may affect the study outcome measures (e.g., active pulmonary tuberculosis)
    4. Suffering from chronic obstructive pulmonary disease (i.e., chronic bronchitis or
    emphysema) and/or other relevant lung diseases causing variable impairment in lung
    function
    5. Hospitalisation for asthma in the 6 months preceding Visit 1
    6. Current or recent (within 3 months of Visit 1) systemic (oral, parenteral or depot)
    corticosteroid therapy or receipt of more than 3 short courses of systemic corticosteroid therapy in the preceding year
    7. Current or recent (within 3 months of Visit 1) use of long-acting β2-agonists (inhaled, oral or otherwise systemic)
    8. Current use of anticholinergics for the relief of asthma symptoms
    9. Asthma exacerbations or respiratory tract infection requiring antibiotic treatment during the past 6 weeks
    10. Known or suspected hypersensitivity to fluticasone or the excipients of either of the pMDIs
    11. Inability to perform lung functions tests
    12. Patients who are unlikely to be compliant, take their medication as directed, complete the diary and daily lung testing procedures or attend scheduled clinic visits
    13. Evidence of current neoplastic or systemic disease or diagnosed tuberculosis
    14. Females who are pregnant or lactating
    15. Any females of childbearing potential who are likely to become pregnant during the course of the study who are not using adequate contraception (i.e., contraceptive pill or barrier method) or will not agree to abstain from sexual intercourse during their participation in the study and for a period of 4 weeks following their final administration of study treatments
    16. Smokers (current or previous)
    17. Evidence of history of alcohol or drug abuse
    18. Participation in an investigational drug trial during 30 days preceding Visit 1
    19. Employees or relatives of employees of Merck Generics or Omnicare Clinical Research Ltd.
    E.5 End points
    E.5.1Primary end point(s)
    Primary efficacy measure is morning peak expiratory flow rate (PEFR) recorded daily with the Vitalograph® 2110 PEF FEV Diary.

    The primary efficacy variable is defined as the mean change in morning PEFR from baseline, where the baseline value is defined as the average of the last 7 days of the run-in period (with day 7 being the day before the randomisation visit). All post- randomisation measurements will be used for calculating the post-baseline average.
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy Yes
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic No
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic Information not present in EudraCT
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans Information not present in EudraCT
    E.7.1.2Bioequivalence study Information not present in EudraCT
    E.7.1.3Other Information not present in EudraCT
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) No
    E.7.3Therapeutic confirmatory (Phase III) Yes
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind Yes
    E.8.1.5Parallel group Yes
    E.8.1.6Cross over No
    E.8.1.7Other Yes
    E.8.1.7.1Other trial design description
    Double-dummy
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) Yes
    E.8.2.2Placebo No
    E.8.2.3Other No
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.5The trial involves multiple Member States Yes
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA Information not present in EudraCT
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    E.8.7Trial has a data monitoring committee Information not present in EudraCT
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years
    E.8.9.1In the Member State concerned months9
    E.8.9.1In the Member State concerned days
    E.8.9.2In all countries concerned by the trial months9
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 Yes
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) Yes
    F.1.1.6Adolescents (12-17 years) Yes
    F.1.2Adults (18-64 years) No
    F.1.3Elderly (>=65 years) No
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Information not present in EudraCT
    F.3.3.1Women of childbearing potential not using contraception For clinical trials recorded in the database before the 10th March 2011 this question read: "Women of childbearing potential" and did not include the words "not using contraception". An answer of yes could have included women of child bearing potential whether or not they would be using contraception. The answer should therefore be understood in that context. This trial was recorded in the database on 2006-05-16. Yes
    F.3.3.2Women of child-bearing potential using contraception Information not present in EudraCT
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally Yes
    F.3.3.6.1Details of subjects incapable of giving consent
    As this is a paeediatric study consent can be given by parent or legal guardian
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state48
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 408
    F.4.2.2In the whole clinical trial 608
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2007-05-05
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2007-06-13
    P. End of Trial
    P.End of Trial StatusCompleted
    EU Clinical Trials Register Service Desk: https://servicedesk.ema.europa.eu
    European Medicines Agency © 1995-2019 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    Legal notice
    EMA HMA